Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Review
Grant support
FS/16/72/32270
British Heart Foundation - United Kingdom
MR/T024062/1
Medical Research Council - United Kingdom
PubMed
37102324
DOI
10.1017/s1047951123000872
PII: S1047951123000872
Knihovny.cz E-resources
- Keywords
- Hypertrophic cardiomyopathy, child, implantable defibrillator, risk factor, sudden cardiac death,
- MeSH
- Defibrillators, Implantable * MeSH
- Child MeSH
- Cardiomyopathy, Hypertrophic * therapy MeSH
- Humans MeSH
- Adolescent MeSH
- Death, Sudden, Cardiac etiology MeSH
- Risk Factors MeSH
- Arrhythmias, Cardiac etiology MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Sudden cardiac death is the most common mode of death during childhood and adolescence in hypertrophic cardiomyopathy, and identifying those individuals at highest risk is a major aspect of clinical care. The mainstay of preventative therapy is the implantable cardioverter-defibrillator, which has been shown to be effective at terminating malignant ventricular arrhythmias in children with hypertrophic cardiomyopathy but can be associated with substantial morbidity. Accurate identification of those children at highest risk who would benefit most from implantable cardioverter-defibrillator implantation while minimising the risk of complications is, therefore, essential. This position statement, on behalf of the Association for European Paediatric and Congenital Cardiology (AEPC), reviews the currently available data on established and proposed risk factors for sudden cardiac death in childhood-onset hypertrophic cardiomyopathy and current approaches for risk stratification in this population. It also provides guidance on identification of individuals at risk of sudden cardiac death and optimal management of implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
Amsterdam University Medical Centre Amsterdam the Netherlands
Centre for Inherited Cardiovascular Diseases Great Ormond Street Hospital London UK
Department of Paediatric Cardiology Helsinki University Children's Hospital Helsinki Finland
Department of Pediatric Cardiology Charite Universitatsmedizin Berlin Berlin Germany
Department of Pediatric Cardiology University of Leiden Leiden the Netherlands
Erasmus MC Sophia Children's Hospital Department of Paediatric Cardiology Rotterdam the Netherlands
References provided by Crossref.org
